NCT07088640

Brief Summary

The multi-step thawing protocol with a reduction of non-permeable cryoprotectant concentrations to reduce osmotic shock caused by the rapid influx of water. Recent studies have shown that a simplified warming protocol by only a thawing solution gave a comparable survival rate but increased pregnancy rate, reduced patients' waiting time, and decreased the workload of embryologists.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
816

participants targeted

Target at P75+ for not_applicable

Timeline
10mo left

Started Aug 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress47%
Aug 2025Mar 2027

First Submitted

Initial submission to the registry

July 20, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 28, 2025

Completed
16 days until next milestone

Study Start

First participant enrolled

August 13, 2025

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2027

Last Updated

September 12, 2025

Status Verified

July 1, 2025

Enrollment Period

1.4 years

First QC Date

July 20, 2025

Last Update Submit

September 10, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Live birth rate

    Live birth is defined as the complete expulsion or extraction from a woman of a product of fertilization, after 22 completed weeks of gestational age; which, after such separation, breathes or shows any other evidence of life, such as heart beat, umbilical cord pulsation or definite movement of voluntary muscles, irrespective of whether the umbilical cord has been cut or the placenta is attached. A birth weight of 500 grams or more can be used if gestational age is unknown

    At 22 weeks of gestation

Secondary Outcomes (20)

  • Survival rate

    At least 2 hours after thawing.

  • Cancellation rate

    Any day during endometrium preparation days before embryo transfer.

  • Positive pregnancy test

    At 2 weeks after embryo placement

  • Implantation rate

    At 3 weeks after embryo placement

  • Clinical pregnancy

    At 5 weeks after embryo placement

  • +15 more secondary outcomes

Study Arms (2)

Single-step thawing protocol

EXPERIMENTAL

For the warming phase, vitrified blastocysts are exposed to the thawing solution of a commercial embryo thawing kit (Irvine Scientific Inc., USA) at 37°C for one minute. Immediately following this, embryos will be rinsed through a 35mm diameter dish of 2ml of pre-equilibrated thawing solution before being placed in culture media in the incubator for at least 2 hours before transfer.

Procedure: Single-step warming protocol by thawing solution only

Multi-step thawing protocol

EXPERIMENTAL

For the Multi-step (MS) protocol, thawing kits were equilibrated overnight in a 37°C incubator. Warming procedures utilized the kits (Cryotech RtU, Japan). To remove the cryoprotectants, blastocysts were warmed, and cryoprotectants were diluted in a three-step process. The warming process starts with the exposure of blastocysts to thaw solution (TS) with 1M trehalose for one minute, set at a temperature to ensure 37°C. Subsequently, blastocysts will be transferred to a second well containing dilution solution (DS) 0.5M trehalose for a two-minute rinse at room temperature. This is followed by two additional three-minute and 30 seconds rinses in the wash solution (WS) at room temperature. The timeline for standard warming of blastocysts requires a total of 6.5 min. After thawing, embryo will be placed in the incubator at least 2 hours before transfer.

Procedure: Standard warming protocol

Interventions

Potentially eligible patients' vitrified blastocysts will be thawed by a single-step thawing protocol. For the warming phase, vitrified blastocysts are exposed to the thawing solution of a commercial embryo thawing kit (Irvine Scientific Inc., USA) at 37°C for one minute. Immediately following this, embryos will be rinsed in a 35mm diameter dish of 2ml of pre-equilibrated thawing solution before being placed in culture media in the incubator for at least 2 hours before transfer.

Also known as: Single-step thawing protocol
Single-step thawing protocol

For the MS protocol, thawing kits were equilibrated overnight in a 37°C incubator. Warming procedures utilized the kits (Cryotech RtU, Japan). To remove the cryoprotectants, blastocysts were warmed, and cryoprotectants were diluted in a three-step process. The warming process starts with the exposure of blastocysts to thaw solution (TS) with 1M trehalose for one minute at 37°C. Subsequently, the blastocyst will be transferred to a second well containing a dilution solution (DS) of 0.5M trehalose for a two-minute rinse at room temperature. This is followed by two additional three-minute and 30-second rinses in the wash solution (WS) at room temperature. The timeline for standard warming of blastocysts requires a total of 6.5 min. After thawing, embryo will be placed in the incubator at least 2 hours before transfer.

Also known as: Multi-step warming protocol
Multi-step thawing protocol

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women aged from 18
  • Undergoing no more than 3 previous IVF/ICSI cycles
  • Had at least a single good-quality blastocyst frozen.
  • Endometrium preparation using artificial cycle
  • Agree to single blastocyst transfer
  • Not participating in any interventional studies at the same time

You may not qualify if:

  • Embryos from cycles after in-vitro maturation, pre-implantation genetic testing (PGT)
  • Having contraindications for exogenous hormone administration (e.g., breast cancer, thromboembolic disease)
  • Having uterine abnormalities (e.g., adenomyosis, intrauterine adhesions, unicornuate/ bicornuate/ arcuate uterus; unremoved hydrosalpinx or endometrial polyp)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

My Duc Hospital

Ho Chi Minh City, City, 7000, Vietnam

RECRUITING

Related Publications (3)

  • Connolly MP, Hoorens S, Chambers GM; ESHRE Reproduction and Society Task Force. The costs and consequences of assisted reproductive technology: an economic perspective. Hum Reprod Update. 2010 Nov-Dec;16(6):603-13. doi: 10.1093/humupd/dmq013. Epub 2010 Jun 8.

    PMID: 20530804BACKGROUND
  • Seki S, Mazur P. The dominance of warming rate over cooling rate in the survival of mouse oocytes subjected to a vitrification procedure. Cryobiology. 2009 Aug;59(1):75-82. doi: 10.1016/j.cryobiol.2009.04.012. Epub 2009 May 7.

    PMID: 19427303BACKGROUND
  • Gallardo M, Saenz J, Risco R. Human oocytes and zygotes are ready for ultra-fast vitrification after 2 minutes of exposure to standard CPA solutions. Sci Rep. 2019 Nov 5;9(1):15986. doi: 10.1038/s41598-019-52014-x.

    PMID: 31690725BACKGROUND

Study Officials

  • Lan TN Vuong, MD, PhD

    University of Medicine and Pharmacy at Ho Chi Minh City

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 20, 2025

First Posted

July 28, 2025

Study Start

August 13, 2025

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

March 1, 2027

Last Updated

September 12, 2025

Record last verified: 2025-07

Locations